Academic Journal
Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.
| Τίτλος: | Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study. |
|---|---|
| Συγγραφείς: | Perrotta N; Department of Physiology and Pharmacology 'V. Erspamer', Sapienza University, Rome, Italy.; Policlinico Umberto I Hospital, Sapienza University, Rome, Italy., Fiorito LA; Department of Physiology and Pharmacology 'V. Erspamer', Sapienza University, Rome, Italy.; Policlinico Umberto I Hospital, Sapienza University, Rome, Italy., Vescovo R; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy., Virgilio A; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy., Amato G; Department of Chemistry and Technology of Drugs, Sapienza University, Rome, Italy., Cimino G; Regional Cystic Fibrosis Center, Policlinico Umberto I Hospital, Sapienza University, Rome, Italy. |
| Πηγή: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2026 Jun; Vol. 92 (6), pp. 1822-1832. Date of Electronic Publication: 2026 Jan 23. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford : Wiley-Blackwell Original Publication: London, Macmillan Journals Ltd. |
| Ιατρικοί όροι (MeSH): | Cystic Fibrosis*/drug therapy , Cystic Fibrosis*/physiopathology , Cystic Fibrosis*/genetics , Cystic Fibrosis*/metabolism , Quinolones*/therapeutic use , Quinolones*/administration & dosage , Indoles*/therapeutic use , Indoles*/administration & dosage , Pyrrolidines*/therapeutic use , Pyrrolidines*/administration & dosage , Aminophenols*/therapeutic use , Aminophenols*/administration & dosage , Aminophenols*/pharmacology , Pyridines*/therapeutic use , Pyridines*/administration & dosage , Pyrazoles*/therapeutic use , Pyrazoles*/administration & dosage , Benzodioxoles*/therapeutic use, Nutritional Status/drug effects ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Lung/drug effects ; Lung/physiopathology ; Chloride Channel Agonists/therapeutic use ; Chloride Channel Agonists/administration & dosage ; Humans ; Female ; Adult ; Male ; Retrospective Studies ; Adolescent ; Young Adult ; Child ; Treatment Outcome |
| Περίληψη: | Aim: Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long-term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30-month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del. Methods: We retrospectively analysed 112 PwCF (median age-31 years) treated with ETI from July 2021 to December 2024. Clinical, spirometric and biochemical data were collected at baseline and at 6, 12, 24 and 30 months. Results: ETI produced sustained lung function gains (percent predicted FEV₁ + 15 points at 24 months, p < 0.001), BMI increase (+1.7 kg/m2 in year-one, p < 0.001) and marked C-reactive protein reduction (-80% at 6 months), with an 85% decrease in pulmonary exacerbations. Nutritional recovery shifted BMI distribution: underweight prevalence declined from 12.5% to 1.8%, while overweight rose from 15.2% to 27.7%. Adolescents improved in weight-for-age Z-scores (+0.42, p = 0.01). Total and LDL cholesterol increased but remained within reference ranges; HDL, triglycerides and glycaemic control stayed stable, with no new cystic fibrosis-related diabetes (CFRD). Vitamin D improved; vitamin B12 fluctuated with supplementation. Mild, transient transaminase elevations occurred in 4.5% of PwCF, with no fibrosis progression (APRI/FIB-4 below risk thresholds). Conclusion: ETI provides durable multisystem benefits, preserving lung function and improving nutritional and metabolic profiles. However, the shift towards overweight/obesity and biochemical signs of hepatic stress suggests evolving cardiometabolic risks. These findings support early ETI initiation and reinforce the need for ongoing monitoring of nutrition, lipid profile and liver function, together with updated CF care strategies to mitigate long-term cardiometabolic complications. (© 2026 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.) |
| References: | Snowball JE, Flight WG, Heath L, Koutoukidis DA. A paradigm shift in cystic fibrosis nutritional care: clinicians' views on the management of patients with overweight and obesity. J Cyst Fibros. 2023;22(5):836‐842. doi:10.1016/j.jcf.2023.03.011. Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019;7(12):e40. doi:10.1016/S2213‐2600(19)30408‐4. Bardin E, Pastor A, Semeraro M, et al. Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem. 2021;213:113195. doi:10.1016/j.ejmech.2021.113195. Frantzen T, Barsky S, LaVecchia G, Marowitz M, Wang J. Evolving nutritional needs in cystic fibrosis. Life. 2023;13(7):1431. doi:10.3390/life13071431. Despotes KA, Ceppe AS, Donaldson SH. Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis. J Cyst Fibros. 2023;22(6):1024‐1026. doi:10.1016/j.jcf.2023.10.002. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor‐Tezacaftor‐ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809‐1819. doi:10.1056/NEJMoa1908639. Moran A, Brunzell C, Cohen RC, et al. CFRD guidelines committee. Clinical care guidelines for cystic fibrosis‐related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697‐2708. doi:10.2337/dc10‐1768. Wilschanski M, Munck A, Carrion E, et al. ESPEN‐ESPGHAN‐ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr. 2024;43(2):413‐445. doi:10.1016/j.clnu.2023.12.017. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi‐ethnic reference values for spirometry for the 3‐95‐yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324‐1343. doi:10.1183/09031936.00080312. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518‐526. doi:10.1053/jhep.2003.50346. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317‐1325. doi:10.1002/hep.21178. Sellers Z, Assis D, Paranjape S, et al. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology. 2024;79(5):1220‐1238. doi:10.1097/HEP.0000000000000646. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double‐blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940‐1948. doi:10.1016/S0140‐6736(19)32597‐8. Vega‐Hernandez G, MacGregor G, Wilfin A, et al. LONGITUDE: an observational study of the long‐term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom cystic fibrosis registry ‐ 2‐year analysis. J Cyst Fibros. 24(4):716‐723. doi:10.1016/j.jcf.2025.04.012. Perrotta N, Fiorito LA, Gentile R, et al. Real‐world evaluation of outcomes and safety of Elexacaftor/Tezacaftor/ivacaftor in pediatric patients with cystic fibrosis: a retrospective study. Clin Transl Sci. 2025;18(10):e70373. doi:10.1111/cts.70373. Keens T, Hoffman V, Topuria I, et al. VX19‐CFD‐003 study group. Real‐world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024;10(7):e28508. doi:10.1016/j.heliyon.2024.e28508. Perrotta N, Fiorito LA, Casini G, et al. Improved clinical outcomes with Elexacaftor/Tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease: real‐world evidence from an Italian single‐center study. Pharmacol Res Perspect. 2025;13(2):e70083. doi:10.1002/prp2.70083. López Cárdenes CM, Merino Sánchez‐Cañete A, Vicente Santamaría S, et al. Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis. Pediatr Pulmonol. 2024;59(12):3632‐3640. doi:10.1002/ppul.27272. Sandersa DB, Zhangb Z, Farrellc P, Lai HCJ. Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. J Cyst Fibros. 2018;17(4):528‐535. doi:10.1016/j.jcf.2018.01.006. Westhölter D, Haubold J, Welsner M, et al. Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT‐based analysis. Sci Rep. 2024;14(1):9465. doi:10.1038/s41598‐024‐59622‐2. Castaldo A, Cimbalo C, Fevola C, et al. The treatment with Elexacaftor/Tezacaftor/ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant. J Cyst Fibros. 24(6):1149‐1155. Pepe A, Fevola C, Dolce D, et al. Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual‐center cohort study. Ther Adv Respir Dis. 2025;19. doi:10.1177/17534666251314706. Bailey J, Krick S, Fontaine KR. The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity. Nutrients. 2022;14(6):1216. doi:10.3390/nu14061216. Castaldo A, Iacotucci P, Bagnasco S, et al. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment. Sci Rep. 2024;14(1):17422. doi:10.1038/s41598‐024‐68511‐7. Vavrina K, Griffin TB, Jones AM, Schindler T, Bui TN, Sankararaman S. Evolving nutrition therapy in cystic fibrosis: adapting to the CFTR modulator era. Nutr Clin Pract. 2025;40(4):816‐828. doi:10.1002/ncp.11332. Ratti GA, Smith H, Mirfakhraee S, et al. Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor‐tezacaftor‐ivacaftor. J Cyst Fibros. 2025;24(1):47‐52. doi:10.1016/j.jcf.2024.09.022. Castaldo A, Gelzo M, Iacotucci P, et al. One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes. Front. Mol. Biosci., 08 January 2024. Sec Cell Biochem. 2023;10. Clayton LJ, Shepherd AI, Corbett J, et al. Cardiovascular function in people with cystic fibrosis on Elexacaftor/Tezacaftor/ivacaftor: a cross‐sectional, observational, single‐Centre study. J Cyst Fibros. 2025;S1569‐1993(25):00052‐00059. doi:10.1016/j.jcf.2025.02.001. Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis and Liver Disease. 2023 Jan 9. In: StatPearls. StatPearls Publishing; 2025. PMID: 32310546. Liang X, Hou X, Bouhamdan M, et al. Sotagliflozin attenuates liver‐associated disorders in cystic fibrosis rabbits. JCI Insight. 2024;9(6):e165826. doi:10.1172/jci.insight.165826. Ticona JH, Lapinel N, Wang J. Future comorbidities in an aging cystic fibrosis population. Life (Basel). 2023;13(6):1305. doi:10.3390/life13061305. Blankenship S, Landis AR, Harrison Williams E, et al. What the future holds: cystic fibrosis and aging. Front Med (Lausanne). 2024;10:1340388. doi:10.3389/fmed.2023.1340388. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis‐related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626‐1631. doi:10.2337/dc09‐0586. Merjaneh L, Hasan S, Kasim N, Ode KL. The role of modulators in cystic fibrosis related diabetes. J Clin Transl Endocrinol. 2021;27:100286. doi:10.1016/j.jcte.2021.100286. Lurquin F, Gohy S. Hermans MP et al combined CFTR modulator therapies are linked with anabolic benefits and insulin‐sparing in cystic fibrosis‐related diabetes. J Clin Transl Endocrinol. 2023;33:100320. doi:10.1016/j.jcte.2023.100320. Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis‐related diabetes: current status and future directions. Diabetes Metab Syndr. 2023;17(11):102899. doi:10.1016/j.dsx.2023.102899. Sankararaman S, Hendrix SJ, Schindler T. Update on the management of vitamins and minerals in cystic fibrosis. Nutr Clin Pract. 2022;37(5):1074‐1087. doi:10.1002/ncp.10899. Hergenroeder GE, Faino A, Bridges G, et al. The impact of elexacaftor/tezacaftor/ivacaftor on fat‐soluble vitamin levels in people with cystic fibrosis. J Cyst Fibros. 2023;22(6):1048‐1053. doi:10.1016/j.jcf.2023.08.002. Crehuá‐Gaudiza E, Vicente Santamaría S, Álvarez Beltrán M, et al. Effect of cystic fibrosis modulator therapies on serum levels of fat‐soluble vitamins. JPGN Rep. 2025;6(2):146‐152. doi:10.1002/jpr3.70007. Jarosz‐Griffiths HH, Caley LR, Lara‐Reyna S, et al. Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium. Heliyon. 2024;10(20):e39244. doi:10.1016/j.heliyon.2024.e39244. Zhang S, Shrestha CL, Robledo‐Avila F, et al. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor. Eur Respir J. 2023;61(4):2102861. doi:10.1183/13993003.02861‐2021. Tewkesbury DH, Athwal V, Bright‐Thomas RJ, Jones AM, Barry PJ. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis Centre. J Cyst Fibros. 2023;22(2):256‐262. doi:10.1016/j.jcf.2023.01.007. |
| Contributed Indexing: | Keywords: Elexacaftor/Tezacaftor/ivacaftor; cystic fibrosis; inflammation; liver function; metabolic health; nutritional status |
| Substance Nomenclature: | 0 (Quinolones) 0 (Indoles) 0 (Pyrrolidines) 0 (Aminophenols) RRN67GMB0V (elexacaftor) 8RW88Y506K (tezacaftor) 0 (Pyridines) 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator) 0 (Pyrazoles) 0 (Benzodioxoles) 0 (Chloride Channel Agonists) |
| Entry Date(s): | Date Created: 20260124 Date Completed: 20260630 Latest Revision: 20260630 |
| Update Code: | 20260701 |
| PubMed Central ID: | PMC13206182 |
| DOI: | 10.1002/bcp.70460 |
| PMID: | 41578635 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!